Novo Nordisk Faces Two Realities: EU Approvals Bolster Pipeline as Canadian Patent Loss and Pricing
Novo Nordisk secures EU backing for oral and high-dose Wegovy but faces Canadian patent loss on Ozempic, triggering…
Browsing Tag